Nature Biotechnology 14, 591 - 593 (1996)

Vaccine R&D success rates and development times

Mark-M. Struck1

The real time saving in vaccine development is not in the preclinical development itself, but in the accelerated clinical development and reduced regulatory process of dossier preparation and review.

  1. 1Mark-M. Struck is head of registration and regulatory affairs at Swiss Serum and Vaccine, Inc., Rehhagstrasse 79, CH-3018 Bern, Switzerland.